Connor, Clark & Lunn Investment Management (CC&L)’s Solid Biosciences SLDB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-721	Closed	-$5K	–	1409
2022 Q3	$5K	Buy	+721	New	+$7.27K	﹤0.01%	1083
2022 Q2	–	Sell	-1,400	Closed	-$25K	–	1190
2022 Q1	$25K	Sell	1,400 -7,952	-85%	-$140K	﹤0.01%	1009
2021 Q4	$245K	Buy	9,352 +3,498	+60%	+$107K	﹤0.01%	931
2021 Q3	$210K	Buy	5,854 +3,714	+174%	+$158K	﹤0.01%	938
2021 Q2	$118K	Sell	2,140 -3,555	-62%	-$235K	﹤0.01%	936
2021 Q1	$472K	Buy	+5,695	New	+$630K	﹤0.01%	798

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SLDB Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Solid Biosciences (SLDB) in Q4 2022, closing a stake of 721 shares — an estimated $5K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SLDB in Q1 2021 and held it in 6 quarters. The position peaked at $472K in Q1 2021. 35 funds tracked by Wall St. Rank hold SLDB as of Q4 2022.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Solid Biosciences position as of Q4 2022 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 721 Solid Biosciences shares in Q4 2022, an estimated $5K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Solid Biosciences in Q1 2021 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Solid Biosciences position peaked at $472K in Q1 2021.
35 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.